

# NaveniBright™ PD1/PD-L1


## ILLUMINATING FUNCTION IN SPATIAL PROTEOMICS

### Detect PD1/PD-L1 interactions *in situ*

Despite the recent success of immune checkpoint inhibitors, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed<sup>1</sup>. PD-L1 IHC is commonly used as a diagnostic marker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear<sup>2</sup>. Navinci has now developed the first commercial *in situ* proximity ligation assay for the specific detection of PD1/PD-L1 interactions *in situ*.


### NaveniBright PD1/PD-L1 enables you to:

- Detect the specific interaction of PD1/PD-L1 using dual recognition
- Identify even low abundance of PD1/PD-L1 interactions
- Visualize PD1/PD-L1 in the tissue micro-environment
- Increase the understanding of PD1/PD-L1 signaling pathways
- Elucidate the potential of the PD1/PD-L1 interaction as a predictive biomarker



## How it works

The NaveniBright PD1/PD-L1 kit is based on our proprietary Naveni® *in situ* proximity ligation technology<sup>3</sup>. The kit includes two Navenibodies conjugated to proprietary oligo arms (depicted as orange antibodies in the illustration to the left). Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct HRP signal.



PD1/PD-L1 interaction in tonsil tissue.

## Ordering information

Product	Code	Read out	Primary antibodies required
NaveniBright PD1/PD-L1	60033	Brightfield	Primary abs included
Naveni PD1/PD-L1 Atto647N	60034	Fluorescence	Primary abs included
Naveni CD8/MHC-I Atto647N	60035	Fluorescence	Primary abs included

Kit size: 4ml working solution.  
For research use only. Not for use in diagnostic procedures.

1. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. *Nat Commun* 11, 3801 (2020).
2. Sánchez-Magraner L, et al., High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. *Cancer Res* 80, 19 (2020).
3. Klaesson A, et al., Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes. *Sci Rep.* 8(1):5400 (2018).



YOU HAVE THE VISION,  
WE HAVE THE SUBSTANCE.

**Your Distributor:**  
BIOMOL GmbH  
Kieler Straße 303a · 22525 Hamburg · Germany  
info@biomol.de · www.biomol.de · www.biomol.com  
Fon: 040-853 260 0 · Fax: 040-853 260 22

**TOLL FREE IN GERMANY:**  
Fon: 0800-246 66 51 · Fax: 0800-246 66 52

For research use only.  
Not for use in diagnostic or therapeutic procedures.

